|
Dr. Tory has a long-term commitment and experience to medical-pharmacological research. He headed the Dept. of Antitumor Chemotherapy, at the Institute for Drug Research, Budapest, and took part in the development of two original antitumor agents. Then he moved to the United States, and worked as a program director at the National Cancer Institute, Frederick, MD.
He worked in the human genome project, developed several genetic markers and took part in building a genetic linkage map of the human chromosome 3. He was a member of the research team that cloned and characterized the von Hippel-Lindau tumor suppressor gene. After returning to Europe he continued to work in the area of tumor biology at the German Cancer Research Center, Heidelberg and at the University Aachen.
The exciting perspective of industrial drug development brought him back to Hungary. He first worked for Biorex, Hungary's first VC pharmaceutical company, and later accepted a position at N-Gene directing cancer research as head of the Molecular Pharmacology Division. | 